Literature DB >> 10562842

Preoperative history and postoperative survival of supratentorial low-grade astrocytomas.

D Afra1, E Osztie, L Sipos, D Vitanovics.   

Abstract

The preoperative history and postoperative course of histologically verified 348 low-grade and 383 anaplastic astrocytomas have been reviewed. In 71.2 and 48.0% of patients epilepsy was the initial symptom of a suspected astrocytoma, and the history was longer than 3 years in 28.1 and 19.5% of cases, respectively. Before the advent of CT, angiography was performed because of a suspected tumour 2-9 years before surgery in 34 cases. The second angiography years later demonstrated the tumour which in 18 cases at surgery proved to be low-grade astrocytoma or anaplastic astrocytoma in 16 cases. During the last 10 years CT or MRI demonstrated a low-density lesion in 21 patients years before surgery. Operation was postponed for different reasons. Ten tumours appeared at 'delayed' surgery as low-grade, but 11 as anaplastic astrocytoma. In the same period 29 further patients were operated on after a history of seizures, longer than 3 years. Histology showed anaplastic astrocytoma in 10 cases also. Malignant transformation occurred nearly in half of the patients during the observation period. This strongly suggests that dedifferentiation is a spontaneous process, an intrinsic feature of astrocytomas and does not depend on any kind of external stimulus. Another 51 patients' surgery was performed following a shorter (1-24 months) history of epilepsy. The 5-year survival rate was 44 and 39.5% Median survival times (53.5 and 51 months) did not show a significant difference between the two groups, but the total survival, including second survivals after reoperation displayed a significant difference (57.5 vs 67.5 months) in favour of patients with a shorter history of seizures. These experiences confirm the difficulties in decision of the time of surgery. Considering the frequent malignant transformation among patients with a long history of seizures, followed by a relatively shorter survival, it may be supposed that an early radical removal in suitable cases might prevent the late dedifferentiation and recurrence.

Entities:  

Mesh:

Year:  1999        PMID: 10562842     DOI: 10.1080/02688699943727

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  14 in total

1.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

2.  Rana catesbeiana ribonuclease induces cell apoptosis via the caspase-9/-3 signaling pathway in human glioblastoma DBTRG, GBM8901 and GBM8401 cell lines.

Authors:  Jen-Ni Chen; Giou-Teng Yiang; Yi-Fan Lin; Pei-Lun Chou; Tsai-Kun Wu; Wei-Jung Chang; Chinshuh Chen; Yung-Luen Yu
Journal:  Oncol Lett       Date:  2015-04-15       Impact factor: 2.967

Review 3.  Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Authors:  Jill M Abrigo; Daniel M Fountain; James M Provenzale; Eric K Law; Joey Sw Kwong; Michael G Hart; Wilson Wai San Tam
Journal:  Cochrane Database Syst Rev       Date:  2018-01-22

Review 4.  Nanotherapeutic systems for local treatment of brain tumors.

Authors:  Rami Walid Chakroun; Pengcheng Zhang; Ran Lin; Paula Schiapparelli; Alfredo Quinones-Hinojosa; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

Review 5.  [Primary brain tumors and brain metastases. Symptomatic epilepsy and driving ability - systematic review and expert opinion].

Authors:  P S Reif; A Strzelczyk; S Rüegg; A H Jacobs; A Haag; A Hermsen; U Sure; S Knake; H M Hamer; H Strik; G Krämer; R Engenhart-Cabilic; F Rosenow
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

6.  Non-enhancing de novo glioblastoma: report of two cases.

Authors:  Aaron A Cohen-Gadol; Michael L DiLuna; Sergei I Bannykh; Joseph M Piepmeier; Dennis D Spencer
Journal:  Neurosurg Rev       Date:  2004-07-28       Impact factor: 3.042

7.  3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study.

Authors:  Su Young Jeong; Tae Hyun Lee; Chang Hun Rhee; A Ra Cho; Byeong Il Kim; Gi Jeong Cheon; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2010-03-04

Review 8.  Low-grade gliomas.

Authors:  Deborah A Forst; Brian V Nahed; Jay S Loeffler; Tracy T Batchelor
Journal:  Oncologist       Date:  2014-03-24

9.  Long-Term Results of stereotactic Brachytherapy (Temporary 125Iodine Seeds) for the Treatment of Low-Grade Astrocytoma (Grade II).

Authors:  Sohrab Shahzadi; Parisa Azimi; Khosrow Parsa
Journal:  Iran Red Crescent Med J       Date:  2013-01-05       Impact factor: 0.611

Review 10.  The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Manish K Aghi; Brian V Nahed; Andrew E Sloan; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.